Clinical trials: Pulmonary Hypertension
Pulmonary Arterial Hypertension
Selonsertib in Adults With Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of selonsertib (GS-4997) on pulmonary vascular resistance (PVR), as measured by right heart catheterization (RHC) in adults with pulmonary arterial hypertension (PAH).
- Trial name
- ARROW (NCT02234141)
- Testing
- Selonsertib
- Where
- 46 sites in United States, Canada and 6 more
- Volunteers
- 151 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH
An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT02652429
- Testing
- Inhaled Nitric Oxide
- Where
- 17 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Arterial Hypertension
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
This is an observational, multicenter, single-day, Phase 2 study. This study will include a 14-day Screening Period and Study Day 1 clinic visit.
- Trial name
- PRN (NCT03888365)
- Testing
- Treprostinil, Non-Treprostinil PAH Medications
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- United Therapeutics
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics
Heart Failure Patients With Pulmonary Hypertension
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension
Prospective, single-arm, multicenter First in Human study to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Pulmonary Hypertension
- Trial name
- PreVail-PH (NCT05951166)
- Testing
- Gradient Denervation System
- Where
- 2 sites in Georgia
- Volunteers
- 5 people
- Sponsor
- Gradient Denervation Technologies
Pulmonary Arterial Hypertension
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to see how much study drug is in the blood of children with pulmonary arterial hypertension (PAH) after dosing to establish the correct dose for further clinical research.
- Trial name
- NCT01484431
- Testing
- Tadalafil- Tablet or Oral suspension
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Pulmonary Hypertension
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521.
- Trial name
- CHEST-2 (NCT00910429)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 73 sites in United States, Argentina and 24 more
- Volunteers
- 237 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
This is a 12-week, international, multicenter, double-blind, three-group, dose-response study to assess the safety and efficacy of BPS-MR in patients with PAH.
- Trial name
- NCT00989963
- Testing
- Beraprost Sodium Modified Release
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 36 people
- Sponsor
- Lung Biotechnology PBC
Pulmonary Arterial Hypertension
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.
- Trial name
- NCT03884465
- Testing
- Inhaled dry powder treprostinil (LIQ861)
- Where
- 3 sites in France, Germany
- Volunteers
- 15 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH).
- Trial name
- NCT00439946
- Testing
- treprostinil, Crono Five ambulatory pump
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension
Study on the Use of Inhaled NO (iNO)
This is a prospective, observational, multicenter study conducted during 1 year in adult and paediatric intensive care units equipped with the EZ-KINOX™ system.
- Trial name
- POSITIVE (NCT02821156)
- Where
- 14 sites in Belgium, France
- Volunteers
- 239 people
- Sponsor
- Air Liquide Santé International
Pulmonary Arterial Hypertension
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
- Trial name
- REPLACE (NCT02891850)
- Testing
- Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
- Where
- 81 sites in United States, Austria and 19 more
- Volunteers
- 225 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Tezosentan in Pulmonary Arterial Hypertension
Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial…
- Trial name
- NCT01077297
- Testing
- Tezosentan
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Hypertension
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
This pilot, non-interventional, company-sponsored, multi-center study documents observational data on patients under routine treatment of Pulmonary Arterial Hypertension (PAH) with inhaled iloprost (using I-Neb device for the…
- Trial name
- COMPHI (NCT01894035)
- Testing
- Iloprost (Ventavis, BAYQ 6256)
- Where
- Portugal
- Volunteers
- 13 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Inhaled Treprostinil for PAH: Open-label Extension
Open-label extension of RIN-PH-302.
- Trial name
- INTREPID - OL (NCT01557660)
- Testing
- inhaled treprostinil
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects
GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 (ACE2).
- Trial name
- NCT03304548
- Testing
- Telephone concept elicitation interview
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)
This Study evaluates the pharmacokinetic (PK) profile of different zamicastat doses in Pulmonary arterial hypertension (PAH) patients to find the most promising therapeutic dosage range for the treatment of PAH disease
- Trial name
- NCT04316143
- Testing
- Oral zamicastat
- Where
- 13 sites in Austria, Germany and 5 more
- Volunteers
- 33 people
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
The development of selexipag for intravenous administration will be useful to avoid treatment interruptions in patients with pulmonary arterial hypertension (PAH) already treated with selexipag administered orally as tablets…
- Trial name
- NCT03187678
- Testing
- i.v. selexipag, oral selexipag (Uptravi)
- Where
- 8 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- Actelion
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
Pre-Eclampsia, Hypertension
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.
- Conditions
- Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia
- Trial name
- NCT03767803
- Testing
- Non-interventional study
- Where
- 24 sites in United States
- Volunteers
- 344 people
- Sponsor
- Progenity, Inc.